



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 11:52
Last Report Issued 08/12/2008 09:37

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 1267SP-POS
Patient ID 1267SP-POS
Chain 1
Age Not Given DOB Not Given
Gender Not Given
Workorder 08001888
Received 07/15/2008 10:41

Sample ID 08001888-001
Matrix Serum or Plasma
Patient Name 1267SP-POS
Patient ID 1267SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes

1267SP Clobazam, Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Table row for Clobazam: 5000 ng/mL, 20, ELEVATED

Synonym(s): Frisium®; Urbanyl®

Following a single 20 mg oral dose, the mean peak
plasma concentration: 465 ng/mL
(range, 220 - 710 ng/mL) after 1.7 hours.

Following a single 40 mg oral dose, the mean peak
plasma concentration: 730 ng/mL at 2.5 hours.
The plasma concentration decreased to
360 ng/mL at 12 hours, 180 ng/mL at 48 hours and
17 ng/mL at 96 hours.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US
Food and Drug Administration.